# Ian Warwick

> Ian Warwick is a Series A investor at Liverpool ChiroChem backing Mobile and Medical. See 8 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Liverpool ChiroChem](https://shizune.co/investors/profile/liverpool-chirochem)
- Total investments: 8
- Last investment: Mar 2021
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/ian-warwick-57784a22/

Ian Warwick is a Series A investor at Liverpool ChiroChem focused on Mobile and Medical. Ian Warwick is the Managing Partner at Deepbridge Capital LLP.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Mobile | 1 | 13% |
| Medical | 1 | 13% |
| Consumer | 1 | 13% |
| Software | 1 | 13% |
| Messaging | 1 | 13% |

14 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 38% |
| Funding Round | 2 | 25% |
| Seed | 1 | 13% |
| Series B | 1 | 13% |
| Private Equity | 1 | 13% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| VoxSmart | VoxSmart is a global communications surveillance software provider headquartered in London, UK with offices in Madrid, Singapore and New York. VoxSmart helps businesses see their communications data in a clear and compliant way to effectively mitigate business risks by delivering critical insights and business intelligence in near real-time.VoxSmart designs, develops, and deploys capture and surveillance solutions that collect all communications sources from phone calls, emails, mobiles right through to WhatsApp into one single monitoring platform. The company's multi-award winning solution, VoxSmart Mobile Capture, empowers organisations to unlock the power of mobility whilst achieving regulatory and internal compliance by recording all mobile communications on any network, anywhere in the world. Mobile Capture is fully compliant and adheres to global regulation, is Cloud based and is deployed remotely with no interference to your user experience.Through recent M&A activity, VoxSmart now provides market leading voice and electronic Communications Surveillance and Automatic Trade Reconstruction technology that helps firms monitor employ conduct and trading activity in an efficient and cost-effective way, while ensuring records can be accurately reconciled within very short time-frames to adhere to global regulation. We pride ourselves in offering the Financial Services the most comprehensive suite of surveillance products that addresses key challenges around data integration, processing and analytics. | $25M |  | Mar 22, 2021 |  |
| VoxSmart | VoxSmart is a global communications surveillance software provider headquartered in London, UK with offices in Madrid, Singapore and New York. VoxSmart helps businesses see their communications data in a clear and compliant way to effectively mitigate business risks by delivering critical insights and business intelligence in near real-time.VoxSmart designs, develops, and deploys capture and surveillance solutions that collect all communications sources from phone calls, emails, mobiles right through to WhatsApp into one single monitoring platform. The company's multi-award winning solution, VoxSmart Mobile Capture, empowers organisations to unlock the power of mobility whilst achieving regulatory and internal compliance by recording all mobile communications on any network, anywhere in the world. Mobile Capture is fully compliant and adheres to global regulation, is Cloud based and is deployed remotely with no interference to your user experience.Through recent M&A activity, VoxSmart now provides market leading voice and electronic Communications Surveillance and Automatic Trade Reconstruction technology that helps firms monitor employ conduct and trading activity in an efficient and cost-effective way, while ensuring records can be accurately reconciled within very short time-frames to adhere to global regulation. We pride ourselves in offering the Financial Services the most comprehensive suite of surveillance products that addresses key challenges around data integration, processing and analytics. | $25M | Private Equity | Mar 22, 2021 |  |
| Touch Biometrix | Touch Biometrix is a company founded in 2017 with the express purpose of developing a revolutionary new fingerprint authentication platform. This will be based on new sensing technology coupled with a new manufacturing model that will deliver high performance fingerprint sensors of any shape or size and at market leading cost points. TouchBiometrix aim to make smart objects even smarter with a new paradigm in user friendly identity authentication.​ | $2.6M | Series A | Apr 18, 2019 |  |
| Touch Biometrix | Touch Biometrix is a company founded in 2017 with the express purpose of developing a revolutionary new fingerprint authentication platform. This will be based on new sensing technology coupled with a new manufacturing model that will deliver high performance fingerprint sensors of any shape or size and at market leading cost points. TouchBiometrix aim to make smart objects even smarter with a new paradigm in user friendly identity authentication.​ | $196K | Seed | May 09, 2018 |  |
| Sky Medical Technology | Sky Medical Technology is a growth-stage bioelectronic medicine platform that completely redefines the way vascular related conditions are treated. The company has developed a neuromodulation therapy called OnPulse™, the first clinically proven bioelectronic compression technology to prevent and treat a wide range of acute and chronic circulatoryconditions. The first indications for the OnPulse wearable therapy are life threatening blood clots, swelling after orthopedic surgery, long term non-healing wounds, as well as applications for pro athletes to speed-up recovery time between games and during travel, conditions experienced by more than forty million people currently with unmet need. | $13.5M | Series B | Sep 01, 2017 |  |
| VoxSmart | VoxSmart is a global communications surveillance software provider headquartered in London, UK with offices in Madrid, Singapore and New York. VoxSmart helps businesses see their communications data in a clear and compliant way to effectively mitigate business risks by delivering critical insights and business intelligence in near real-time.VoxSmart designs, develops, and deploys capture and surveillance solutions that collect all communications sources from phone calls, emails, mobiles right through to WhatsApp into one single monitoring platform. The company's multi-award winning solution, VoxSmart Mobile Capture, empowers organisations to unlock the power of mobility whilst achieving regulatory and internal compliance by recording all mobile communications on any network, anywhere in the world. Mobile Capture is fully compliant and adheres to global regulation, is Cloud based and is deployed remotely with no interference to your user experience.Through recent M&A activity, VoxSmart now provides market leading voice and electronic Communications Surveillance and Automatic Trade Reconstruction technology that helps firms monitor employ conduct and trading activity in an efficient and cost-effective way, while ensuring records can be accurately reconciled within very short time-frames to adhere to global regulation. We pride ourselves in offering the Financial Services the most comprehensive suite of surveillance products that addresses key challenges around data integration, processing and analytics. | $7M | Series A | Feb 07, 2017 |  |
| Sky Medical Technology | Sky Medical Technology is a growth-stage bioelectronic medicine platform that completely redefines the way vascular related conditions are treated. The company has developed a neuromodulation therapy called OnPulse™, the first clinically proven bioelectronic compression technology to prevent and treat a wide range of acute and chronic circulatoryconditions. The first indications for the OnPulse wearable therapy are life threatening blood clots, swelling after orthopedic surgery, long term non-healing wounds, as well as applications for pro athletes to speed-up recovery time between games and during travel, conditions experienced by more than forty million people currently with unmet need. | $15M | Series A | Feb 01, 2015 |  |
| Sky Medical Technology | Sky Medical Technology is a growth-stage bioelectronic medicine platform that completely redefines the way vascular related conditions are treated. The company has developed a neuromodulation therapy called OnPulse™, the first clinically proven bioelectronic compression technology to prevent and treat a wide range of acute and chronic circulatoryconditions. The first indications for the OnPulse wearable therapy are life threatening blood clots, swelling after orthopedic surgery, long term non-healing wounds, as well as applications for pro athletes to speed-up recovery time between games and during travel, conditions experienced by more than forty million people currently with unmet need. |  |  | Jan 01, 2013 |  |

8 of 8 investments shown.

## Co-investors
- [Juno Capital Partners](https://shizune.co/investors/profile/juno-capital) — VC Fund, 3 deals together
- [Toscafund Asset Management](https://shizune.co/investors/profile/toscafund-asset-management) — VC Fund, 2 deals together
- [ACF Investors](https://shizune.co/investors/profile/angel-cofund) — VC Fund, 1 deal together
- [Longbow Capital](https://shizune.co/investors/profile/longbow-capital) — VC Fund, 1 deal together

## About Liverpool ChiroChem

VC Fund · Liverpool, United Kingdom

Liverpool ChiroChem (LCC) is a chemistry-based CRO that produces chiral small molecules for biotech/pharmaceutical R&D. Their specialist products can be used as building blocks, fragments and screening compounds to enable small molecule drug discovery. their chemical technologies provide efficient access to novel chiral building blocks forhit identification and hit-to-lead optimization.LCC’s catalytic methods give access to a wide range of chiral amines in excellent enantiomeric purity. Their initial focus is on the production and supply of chiral piperidines and other sp3-rich nitrogen heterocycles , which are of great importance to drug discovery and development due to their excellent pharmacokinetic properties e.g. improved solubility and bioavailability. LCC's technologies were developed through years of research in the areas of asymmetric hydrogenation and Pd-coupling. LCC now provide collaborate services with their customers to optimise key steps in synthetic routes.

5 contacts available at Liverpool ChiroChem.

| Name | Title | Profile |
| --- | --- | --- |
| Ian Warwick | Director | https://shizune.co/investors/profile/ian-warwick |
| Jiwu Ruan | Co-founder and CSO | https://shizune.co/investors/profile/jiwu-ruan |
| Paul Colbon | Co-founder & CEO | https://shizune.co/investors/profile/paul-colbon |
| Philip Tottey | CFO | https://shizune.co/investors/profile/philip-tottey |
| Samuel Kirkwood | Business Development Manager | https://shizune.co/investors/profile/samuel-kirkwood |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Ian Warwick invest in?

Ian Warwick invests primarily in Mobile, Medical and Consumer startups, most often at Series A and Funding Round stage. Most of the 8 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Ian Warwick last invest?

The most recent investment recorded for Ian Warwick closed in Mar 2021. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co